Healios K.K (TYO:4593) and Nobelpharma terminated discussions regarding a development and commercialization agreement for MultiStem in Japan, according to a Wednesday filing on the Tokyo Stock Exchange.
The decision follows unsuccessful renegotiations on the terms of the agreement after Healios opted not to proceed with a Phase 3 trial in Japan, as it was deemed unnecessary.
Price (JPY): $200.00, Change: $-1.0, Percent Change: -0.50%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。